Last reviewed · How we verify
tumor necrosis factor inhibitors (TNFi) (tumor-necrosis-factor-inhibitors-tnfi)
Tumor necrosis factor inhibitors (TNFi) from Pfizer Inc. are used to treat various inflammatory conditions. They work by inhibiting the action of tumor necrosis factor, a protein involved in inflammation. Key indications include Rheumatoid Arthritis, Psoriatic Arthritis, and Plaque Psoriasis. TNFi drugs have shown clinical differentiation in reducing symptoms and improving quality of life for patients. Commercially, they have been highly significant, generating $63.6B in revenue. Pipeline developments for TNFi drugs are ongoing, with researchers exploring new indications and formulations.
At a glance
| Generic name | tumor-necrosis-factor-inhibitors-tnfi |
|---|---|
| Sponsor | Pfizer |
| Drug class | biologic |
| Target | tumor necrosis factor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Juvenile Idiopathic Arthritis
- Plaque Psoriasis
- Ulcerative Colitis
- Crohn's Disease
- Axial Spondyloarthritis
- Psoriatic Arthritis with Distal Interphalangeal Involvement
- Non-Radiographic Axial Spondyloarthritis
- Moderate to Severe Ulcerative Colitis
- Moderate to Severe Crohn's Disease
- Active Ankylosing Spondylitis
- Moderate to Severe Plaque Psoriasis
- Active Psoriatic Arthritis
- Active Rheumatoid Arthritis
- Juvenile Idiopathic Arthritis with Polyarticular Course
- Juvenile Idiopathic Arthritis with Enthesitis
- Juvenile Idiopathic Arthritis with Oligoarticular Course
- Juvenile Idiopathic Arthritis with Systemic Features
Common side effects
- Injection site reaction
- Diarrhoea
- Nasopharyngitis
- Upper respiratory tract infection
- Arthralgia
- Back pain
- Urinary tract infection
- rash
- autoimmune disorder
- otitis media
- tooth infection
- urticaria
Drug interactions
- Abatacept
- Anakinra
- Azathioprine
- Cyclophosphamide
- Cyclosporine
- Etanercept
- Glatiramer acetate
- Hydroxychloroquine
- Immunosuppressants (e.g., azathioprine, cyclophosphamide, cyclosporine)
- Live vaccines
- Methotrexate
- Mycophenolate mofetil
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM) (PHASE4)
- Stand UP to Rheumatoid Arthritis (SUPRA) (NA)
- Lipids, Inflammation, and CV Risk in RA
- A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
- COVID-19 VaccinE Response in Rheumatology Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tumor necrosis factor inhibitors (TNFi) CI brief — competitive landscape report
- tumor necrosis factor inhibitors (TNFi) updates RSS · CI watch RSS
- Pfizer portfolio CI